DOCSLIB.ORG

Chakiba Et Al NEJM 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chakiba Et Al NEJM 2018 PMID First author Title Journal 24557436 Acevedo-Gadea C Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination InternationalWith Oral Topotecan Journal offor Gynecological Recurrent and Cancer Advanced Endometrial Cancer 24947095 Advani SH Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients withIndian advanced J Cancer cancer. 25052451 Agarwal N Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients WithOncologist Metastatic Urothelial Carcinoma 24907635 Aglietta M A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine inAnn chemotherapy-naive Oncol patients with metastatic pancreatic cancer. 24743052 Alrwas A Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxelMelanoma combined Research with interleukin-2 and interferon-[alpha] in patients with metastatic melanoma. 24405565 Ando Y Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in JapaneseCancer patients Science with advanced solid tumors. 24563479 Angevin E A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 MonoclonalClin Antibody, Cancer Resin Patients with Advanced Solid Tumors 25482239 Ansell SM PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma N Eng J Med 24416138 Aparicio J A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapyPlos in patients One with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. 24606884 Aruga A Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancerJ Transl Med 24434430 Bauer S Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinalBr J Cancer stromal tumors. 25149088 Becerra CR A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advancedCancer solid Chemother tumors. Pharmacol 25142843 Bellmunt J Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line TreatmentOncologist of Metastatic or Unresectable Renal Cell Carcinoma 24819685 Bendell JC Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 inCancer subjects Chemother with advanced Pharmacol solid tumors. 24173543 Bendell JC Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-likeClin Cancer Res kinase-1 ligand trap, in patients with advanced cancer. 25411085 Bendell JC Phase 1, Open-Label, Dose EscalaHon0 Safety0 and Pharmaco3ineHcs Study of ME-344 as a Single AgentCancer in 24691674 Bendell JC Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-lineInvest New treatment Drugs for patients with metastatic colorectal cancer 24368401 Besse B IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII phase Ib dose-escalaHon study of everolimus combined 2ith cisplaHn and etoposide as Jrst-lineAnn therap Oncoly in paHents 2ith extensive-stage small-cell lung cancer 24685058 Bitting RL A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in PatientsClinical With Genitourinary Advanced Renal Cancer Cell Carcinoma 25327558 Blumenthal GM A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors Oncotarget 23665950 Boku N Phase I study of suniHnib plus S-1 and cisplaHn in Japanese paHents 2ith advanced or metastaHc Investgastric New cancer. Drugs 25290091 Brana I A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination withB J Cancer the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. 24395457 Britten CD Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patientsInvest with advancedNew Drugs cancer. 25102375 Cabanillas ME A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer Thyroid 24942404 Calvo E Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexedInvest New and Drugscisplatin in patients with advanced cancer. 24627219 Chan S A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicinCancer as first-line Chemother treatment Pharmacol in metastatic breast cancer 25577133 Chang TC Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Cancer Chemother Pharmacol 25312684 Chawla SP A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma Cancer 25393368 Chen EX A Phase I study of cyclin-dependent 3inaseinhibitor 0 AT75190 in paHents 2ith advanced cancerC N BrI J Cancerlinical Trials Group IND 177 25752751 Cheson BD A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomasBr J Haematol 24346101 Chiappori A Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsedJournal non-small-cell of Thoracic Oncology lung cancer. 24711549 Chien AJ Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With HumanJ Clin Epidermal Oncol Growth Factor Receptor 2–Overexpressing Breast Cancer 24452395 Chiorean EG A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonalCancer Chemother antibody, Pharmacol in patients with advanced solid tumors. 25536954 Choy E Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination With DoxorubicinCancer in Patients With Metastatic Sarcoma 24108668 Ciunci CA Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients withCancer advanced cancer. 24916770 Cleary JM A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination withInvest gemcitabine New Drugs in patients with solid tumors. 24983373 Cohen SJ Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheresB J Cancer (SIR-Spheres) in patients with advanced cancer. 25270361 Cohn A A phase I dose-escalaHon study to a predeJned dose of a transforming gro2th factor-N1 monoclonalInternational journal of oncology 25403209 Conlon KC Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine productionJ Clin Oncol during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. 24740268 Costello BA Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors Invest New Drugs 25542057 Coupe N PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelEur J Cancer 24610297 Curtis KK Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients Cancerwith advanced Chemother LHRH-receptor-expressing Pharmacol solid tumors 25605849 Daud AI Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in CombinationJ Clin Oncol With Gemcitabine in Patients With Advanced Solid Tumors 25025963 Del Conte G Phase I study of olaparib in combinaHon2ith liposomal doxorubicin in paHents 2ith advanced solidBr tumours J Cancer 24262587 Delord JP Open-label0 mulHcentre expansion cohort to evaluate imgatuzumab in pre-treated paHents 2ith ARAS-mutantEur J Cancer 25059319 Doi T Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced Cancersolid tumors Chemother Pharmacol 24297161 Dunbar EM Phase 1 trial of dichloroacetate 9D A: in adults 2ith recurrentmalignant brain tumors Invest New Drugs 24563480 Elez ME First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid TumorsClin Cancer Res 24518092 Ellis PM N I TG IND.190 Phase I Trial of Dalotuzumab 9MA-0646: in ombinaHon 2ith isplaHn and EtoposideJournal ofin Extensive-StageThoracic Oncology Small- ell 7ung ancer 24714750 Eskens FA A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxelBr J Cancer in advanced solid tumours 25135998 Fanale MA Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas:J Clin resultsOncol of a phase I study. 25183650 Figg WD A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patientsCancer with refractoryChemother neoplasms. Pharmacol 24615776 Flinn IW Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treatedBlood indolent non-Hodgkin lymphoma 24141374 Floquet A Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phaseCancer I dose-finding Chemother study. Pharmacol 24306314 Fu S Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advancedInvest malignancies New Drugs 25065668 Fumoleau P A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053The Breast Lapatam study) 25153538 Gadgeel SM Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistantLancet
Load more

Recommended publications
  • Anti-HER3 Monoclonal Antibody Patritumab Sensitizes Refractory Non-Small Cell Lung Cancer to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
    Oncogene (2016) 35, 878–886 © 2016 Macmillan Publishers Limited All rights reserved 0950-9232/16 www.nature.com/onc ORIGINAL ARTICLE Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib K Yonesaka1, K Hirotani2, H Kawakami1, M Takeda1, H Kaneda1, K Sakai3, I Okamoto4, K Nishio3, PA Jänne5,6,7 and K Nakagawa1 Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a monoclonal antibody against HER3 that has shown promising results in early-phase clinical trials, but an optimal target population for the drug has yet to be identified. In the present study, we examined whether heregulin, a HER3 ligand that is also overexpressed in a subset of NSCLC, can be used as a biomarker to predict the antitumorigenic efficacy of patritumab and whether the drug can overcome the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistance induced by heregulin. Patritumab sensitivity was associated with heregulin expression, which, when abolished, resulted in the loss of HER3 and AKT activation and growth arrest. Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. Sustained HER3-AKT activation was blocked by combining erlotinib with either anti-HER2 or anti-HER3 antibody. Notably, heregulin was upregulated in tissue samples from an NSCLC patient who had an activating EGFR mutation but was resistant to the TKI gefitinib.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Advanced Development of Erbb Family-Targeted Therapies in Osteosarcoma Treatment
    Investigational New Drugs (2019) 37:175–183 https://doi.org/10.1007/s10637-018-0684-8 REVIEW Advanced development of ErbB family-targeted therapies in osteosarcoma treatment Wei Wang1 & Hua-fu Zhao2 & Teng-fei Yao1 & Hao Gong1 Received: 19 August 2018 /Accepted: 16 October 2018 /Published online: 24 October 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Summary Osteosarcoma (OS) is the most common primary aggressive and malignant bone tumor. Newly diagnostic OS patients benefit from the standard therapy including surgical resection plus radiotherapy and neoadjuvant chemotherapy (MAP chemotherapy: high-dose methotrexate, doxorubicin and cisplatin). However, tumor recurrence and metastasis give rise to a sharp decline of the 5-year overall survival rate in OS patients. Little improvement has been made for decades, urging the development of more effective therapeutic approaches. ErbB receptor family including EGFR, HER2, HER3 and HER4, being important to the activation of PI3K/Akt and MAPK signaling pathways, are potential targets for OS treatment. Genetic aberrations (amplification, overexpression, mutation and altered splicing) of ErbB are essential to the growth, apoptosis, motility and metastasis in a variety of cancers. Overexpression of ErbB family is associated with the poor prognosis of cancer patients. A number of monoclonal antibodies or inhibitors specific for ErbB family have entered clinical trials in a range of solid tumors including breast carcinoma, lung carcinoma and sarcoma. Here, we summarized
    [Show full text]
  • A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent
    Author Manuscript Published OnlineFirst on August 30, 2019; DOI: 10.1158/1078-0432.CCR-19-1745 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization Authors: Yuuri Hashimoto1, Kumiko Koyama1, Yasuki Kamai1, Kenji Hirotani1, Yusuke Ogitani1, Akiko Zembutsu1, Manabu Abe1, Yuki Kaneda1, Naoyuki Maeda1, Yoshinobu Shiose1, Takuma Iguchi1, Tomomichi Ishizaka1, Tsuyoshi Karibe1, Ichiro Hayakawa1, Koji Morita1, Takashi Nakada1, Taisei Nomura2, Kenichi Wakita1, Takashi Kagari1, Yuki Abe1, Masato Murakami1, Suguru Ueno1, and Toshinori Agatsuma1 Affiliations: 1Daiichi Sankyo Co., Ltd., Tokyo, Japan, 2National Institute of Biomedical Innovation, Health and Nutrition, Osaka, Japan Running Title: Preclinical evaluation of U3-1402, a HER3-targeting ADC Keywords: HER3, ADC, DNA topoisomerase I inhibitor, antibody, internalization Corresponding author: Yasuki Kamai, PhD, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan; Phone: +81 3 3492 3131; Fax: +81 3 5436 8578; E-mail: [email protected] Conflict of Interest: Taisei Nomura undertakes collaborative work with Daiichi Sankyo Co., Ltd, and declares no conflict of interest associated with this manuscript. Other authors are employees of Daiichi Sankyo Co., Ltd., and declare no potential conflicts of interest. 1 Downloaded from clincancerres.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 30, 2019; DOI: 10.1158/1078-0432.CCR-19-1745 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
    cancers Review HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors Kimio Yonesaka Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi Osaka-Sayamashi, Osaka 589-8511, Japan; [email protected]; Tel.: +81-72-366-0221; Fax: +81-72-360-5000 Simple Summary: Epidermal growth factor receptor (EGFR) is one of the anticancer drug targets for certain malignancies including nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma. However, the grave issue of drug resistance through diverse mechanisms persists. Since the discovery of aberrantly activated human epidermal growth factor receptor-2 (HER2) and HER3 mediating resistance to EGFR-inhibitors, intensive investigations on HER2- and HER3-targeting treatments have revealed their advantages and limitations. An innovative antibody-drug conjugate (ADC) technology, with a new linker-payload system, has provided a solution to overcome this resistance. HER2-targeting ADC trastuzumab deruxtecan or HER3-targeting ADC patritumab deruxtecan, using the same cleavable linker-payload system, demonstrated promising responsiveness in patients with HER2-positive CRC or EGFR-mutated NSCLC, respectively. The current manuscript presents an overview of the accumulated evidence on HER2- and HER3-targeting therapy and discussion on remaining issues for further improvement of treatments for cancers resistant to EGFR-inhibitors. Abstract: Epidermal growth factor receptor (EGFR) is one of the anticancer drug targets for certain Citation: Yonesaka, K. malignancies, including nonsmall cell lung cancer (NSCLC), colorectal cancer (CRC), and head HER2-/HER3-Targeting and neck squamous cell carcinoma. However, the grave issue of drug resistance through diverse Antibody—Drug Conjugates for mechanisms persists, including secondary EGFR-mutation and its downstream RAS/RAF mutation.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • Daiichi Sankyo to Present New Data for HER2 and HER3 Directed Dxd Adcs at SABCS
    Press Release Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS • Longer follow-up research data for ENHERTU® based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term safety profile to be highlighted • New data from expansion cohorts of phase 1/2 study of patritumab deruxtecan in patients with HR positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression or patients with HER3 high triple negative breast cancer to be presented for first time • Daiichi Sankyo to hold Virtual R&D Day to discuss key SABCS data and provide future clinical development plans across its oncology portfolio Munich and Basking Ridge, NJ – (November 17, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will present new research data for ENHERTU® (fam-trastuzumab deruxtecan-nxki) and patritumab deruxtecan (U3-1402; HER3-DXd), two of its lead DXd antibody drug conjugates (ADC), at the 2020 San Antonio Breast Cancer Symposium (#SABCS20) virtual conference to be held December 8-11, 2020. Updated results from the pivotal phase 2 DESTINY-Breast01 trial of ENHERTU, a HER2 directed ADC, reporting updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term safety seen in previously treated patients with HER2 positive metastatic breast cancer will be presented as a Spotlight Poster Discussion. A first look at new data from the phase 1/2 trial of patritumab deruxtecan, a HER3 directed ADC, reporting on four expansion cohorts of patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression and triple negative breast cancer with higher levels of HER3 expression will also be presented.
    [Show full text]
  • Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent Or Metastatic Squamous
    Author Manuscript Published OnlineFirst on October 16, 2018; DOI: 10.1158/1078-0432.CCR-18-1539 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study Magnus Dillon,1 Lorna Grove,1 Kate Newbold,1 Heather Shaw,2 Nicholas Brown,2 Jeanne Mendell,3 Shuquan Chen,3 Robert A. Beckman,4 Anne Jennings,2 Marivic Ricamara,2 Jonathan Greenberg3 Martin Forster,2* and Kevin J. Harrington1* 1Royal Marsden Hospital/Institute of Cancer Research, National Institute of Health Research Biomedical Research Center, London, UK. 2Department of Oncology, University College London/University College London Hospitals, London, UK. 3Daiichi Sankyo, Edison, NJ, USA. 4Departments of Oncology and of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC, USA. *MF and KJH are joint senior authors. Running title (54/60 characters): Patritumab + cetuximab + platinum therapy in R/M SCCHN Key words (5/5): patritumab, cetuximab, recurrent or metastatic squamous cell carcinoma of the head and neck, safety, dose-limiting toxicity Abbreviations: AE, adverse event; AUC, area under the curve; Cmax, maximum concentration; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicity; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; HAHA, human antihuman 1 Downloaded from clincancerres.aacrjournals.org on September 23, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on October 16, 2018; DOI: 10.1158/1078-0432.CCR-18-1539 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • EP3027208T3.Pdf
    RZECZPOSPOLITA (12) TŁUMACZENIE PATENTU EUROPEJSKIEGO (19) PL (11) PL/EP 3027208 POLSKA (13) T3 (96) Data i numer zgłoszenia patentu europejskiego: (51) Int.Cl. 30.07.2014 14750331.2 A61K 39/395 (2006.01) G01N 33/50 (2006.01) (97) O udzieleniu patentu europejskiego ogłoszono: 24.06.2020 Europejski Biuletyn Patentowy 2020/26 Urząd Patentowy EP 3027208 B1 Rzeczypospolitej Polskiej (54) Tytuł wynalazku: DIAGNOZA I TERAPIA NOWOTWORU Z UDZIAŁEM NOWOTWOROWYCH KOMÓREK MACIERZYSTYCH (30) Pierwszeństwo: 31.07.2013 WO PCT/EP2013/002272 (43) Zgłoszenie ogłoszono: 08.06.2016 w Europejskim Biuletynie Patentowym nr 2016/23 (45) O złożeniu tłumaczenia patentu ogłoszono: 02.11.2020 Wiadomości Urzędu Patentowego 2020/17 (73) Uprawniony z patentu: BioNTech SE, Mainz, DE Astellas Pharma Inc., Tokyo, JP TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH, Mainz, DE (72) Twórca(y) wynalazku: UGUR SAHIN, Mainz, DE ÖZLEM TÜRECI, Mainz, DE KORDEN WALTER, Saulheim, DE MEIKE WAGNER, Mainz, DE MARIA KREUZBERG, Aachen, DE SABINE HÄCKER, Mainz, DE T3 STEFAN JACOBS, Mainz, DE (74) Pełnomocnik: rzecz. pat. Dariusz Mielcarski 3027208 KANCELARIA PATENTOWA LION & LION ul. M. Karłowicza 24/1 80-275 Gdańsk PL/EP Uwaga: W ciągu dziewięciu miesięcy od publikacji informacji o udzieleniu patentu europejskiego, każda osoba może wnieść do Europejskiego Urzędu Patentowego sprzeciw dotyczący udzielonego patentu europejskiego. Sprzeciw wnosi się w formie uzasadnionego na piśmie oświadczenia. Uważa się go za wniesiony dopiero z chwilą wniesienia opłaty za sprzeciw (Art. 99 (1) Konwencji o udzielaniu patentów europejskich). LL-20/870 EP 3 027 208 B1 Opis [0001] Konwencjonalne terapie przeciwnowotworowe próbowały głównie selektywnie wykrywać i eliminować komórki nowotworowe, które w dużej mierze szybko rosną (tj.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]